Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis

Aim PD-1/PD-L1 inhibitors in combination with CTLA-4 inhibitors are being tested in a number of ongoing clinical trials. As a result, it is critical to fully comprehend the toxicity characteristics of adverse events in combination therapy. This study aims to extensively compare the incidences and OR...

Full description

Bibliographic Details
Main Authors: Ze Mi, Yunshu Zhang, Zhichao Feng, Jiahao Liu, Jianmin Wu, Hongpei Tan, Xiaoqian Ma, Zhenguo Liu, Pengfei Rong
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Artificial Cells, Nanomedicine, and Biotechnology
Subjects:
PD-1/PD-L1 inhibitors
CTLA-4 inhibitors
combination therapy
treatment-related adverse events
Online Access:https://www.tandfonline.com/doi/10.1080/21691401.2022.2131354

Internet

https://www.tandfonline.com/doi/10.1080/21691401.2022.2131354

Similar Items